The Molecular Mechanisms of Traditional Chinese Medicine ZHENG Syndromes on Pancreatic Tumor Growth

Abstract

Background: Traditional Chinese medicine (TCM) syndromes (ZHENG in Chinese) are the abstraction from the comprehensive analysis of clinical information gained by the four main diagnostic TCM methods: observation, listening, questioning, and pulse analyses. Proper TCM diagnosis is the most important principle to guide the prescribing of Chinese herbs. Objective: To evaluate the specific effect of TCM ZHENG on tumor growth and to examine the molecular mechanisms underlying ZHENG and tumor growth. Methods: The authors established subcutaneous tumor models of pancreatic cancer ZHENG syndromes of Damp heat (Shi-Re) and Spleen deficiency (Pi-Xu). Tissue samples of the subcutaneous transplanted tumors from each model were studied versus control tumors. CCR5 and CXCR4 proteins in these tissues were assayed by immunohistochemical staining. The expression of CCR5/CCL5/CCL4/CCL3 and CXCR4/SDF-1 mRNA was investigated by reverse transcriptase—polymerase chain reaction (RT-PCR). SDF-1, CCL4, CCL5, and CCL3, which are ligands of CXCR4 and CCR5, were examined by ELISA. Results: The study found that tumor models with different ZHENG were successfully established in each group; the tumor growth of Shi-Re group was slower than that of the control group. It was found that there was a significant difference in CCR5 mRNA expression levels among the Pi-Xu, Shi-Re, and control groups. The results of immunohistochemistry staining revealed that the positive rate of CCR5 protein in Shi-Re group, Pi-Xu group, and control group was 25.00%, 53.33%, 83.33%, respectively. The Shi-Re group expressed the lowest levels of CCL5 and CCL4. Conclusion: The results of the study suggest that the existence of TCM ZHENG may influence the tumor growth in pancreatic cancer, which might be mediated by the expression of CCR5/CCL5/CCL4. This finding may lead to the development of TCM ZHENG as a prognostic indicator in pancreatic tumor growth.

Keywords

pancreatic cancer ZHENG CCR5/CCL5/CCL4 CXCR4/SDF-1 traditional Chinese medicine Pi-Xu Shi-Re tumor micro environment personalized therapy

References

Dobos GJ , Tan L. , Cohen MH , et al. Are national quality standards for traditional Chinese herbal medicine sufficient? Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Complement Ther Med. 2005;13:183-190.

Molassiotis A. , Fernandez-Ortega P. , Pud D. , et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16:655-663.

Kong Y. , Jiang Q. The discussion of treatment based on syndrome differentiation and personalized therapy of cancer. Lishizhen Med Materia Medica Res. 2009;20:752-753.

Xu L. , Sun D. -Z, Liu L. , Wei P. -K. Expression of tumor metastasis-related gene protein in the same syndromic classification of gastric carcinoma on traditional Chinese medicine. World Chin J Digestol. 2004;12:2782-2787.

You-xin Y. , Hong-xia Y. , Er-qing D. , et al. Relativity study of pathology variation and syndrome types of TCM on precancerous lesion of chronic atrophic gastritis patients. J Tianjin Univ Tradit Chin Med. 2006;25:207-209.

Fan Z. , Liang F. , Li Q. Analysis of TCM treatment of advanced pancreatic cancer. Liaoning J Tradit Chin Med. 2008;35: 679-681.

Liu L. , Song M. Experience of Yuerrxin About TCM Treatment of Liver Cancer. Beijing, China: People’s Medical Publishing House ; 2004:177.

Lu G. , Shaoxian L. Establishment and evaluation of animal models of Spleen-stomach Damp-heat syndrome. J Guangzhou Univ Tradit Chin Med. 2005;22:231-235.

Deprez RHL , Fijnvandraat AC , Ruijter JM , Moorman AFM. Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions . Anal Biochem. 2002;307:63-69.

10.

Dhillon N. , Aggarwal BB , Newman RA , et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491-4499.

11.

Ryan JL , Marsh L. , Ling M. , et al. Curcumin improves radiation dermatitis in breast cancer patients: interim analysis of randomized, double-blind, placebo-controlled clinical trial. J Invest Dermatol. 2009;129:S51-S51.

12.

Xue Y. , Wen-Chao L. Treatment based on syndrome differentiation and molecular targeted therapy of cancer medicine and philosophy. Clin Decis Making Forum Ed. 2009;30:68-69.

13.

Gu CongDe . The Yellow Emperor’s Inner Classic, Essential Questions [Chinese name: Huangdi Neijing, Suwen]. 1956.

14.

Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-573.

15.

Vaday GG , Peehl DM , Kadam PA , Lawrence DM Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006;66:124-134.

16.

Luker KE , Luker GD Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett . 2006;238:30-41.

17.

Kucia M. , Reca R. , Miekus K. , et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879-894.

18.

Rollins BJ Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006;42:760-767.

19.

Muller A. , Homey B. , Soto H. , et al. Involvement of chemokine receptors in breast cancer metastasis . Nature. 2001;410: 50-56.

20.

Koshiba T. , Hosotani R. , Miyamoto Y. , et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression . Clin Cancer Res. 2000;6:3530-3535.

21.

Wehler T. , Wolfert F. , Schimanski CC , et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep. 2006;16:1159-1164.

22.

Soria G. , Ben-Baruch A. The CCL5/CCR5 axis in cancer. In: Fulton AM , ed. Chemokine Receptors in Cancer. New York, NY: Humana Press; 2009 :109-130.

23.

Mueller A. , Strange PG Mechanisms of internalization and recycling of the chemokine receptor, CCR5 . Eur J Biochem. 2004;271:243-252.

24.

Trentin L. , Miorin M. , Facco M. , et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol. 2007;138: 594-602.

25.

Manes S. , Mira E. , Colomer R. , et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med. 2003 ;198:1381-1389.

26.

Tan MCB , Goedegebuure PS , Belt BA , et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182:1746-1755.

27.

Niwa Y. , Akamatsu H. , Niwa H. , Sumi H. , Ozaki Y. , Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res . 2001;7:285-289.

28.

Bieche I. , Lerebours F. , Tozlu S. , Espie M. , Marty M. , Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004;10:6789-6795.

29.

Uekusa Y. , Yu WG , Mukai T. , et al. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res. 2002;62:3751-3758.

30.

Mellado M. , de Ana AM , Moreno MC , Martinez C. , Rodriguez-Frade JM A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol. 2001;11:691-696.